Hepatocellular carcinoma surgery outcomes in the developing world: A 20-year retrospective cohort study at the National Cancer Institute of Peru  by Ruiz, Eloy et al.
Hepatocellular carcinoma
surgery outcomes in the
developing world: A 20-year
retrospective cohort study at [3_TD$DIFF]
the National Cancer Institute
of Peru
Eloy Ruiz a, Teresa Rojas Rojas b, Francisco Berrospi a, Ivan Chávez a,
Carlos Luque a, Luis Cano c, Franco Doimi c, Pascal Pineau d,e, Eric Deharo f,g,
Stéphane Bertani f,h,*
a Instituto Nacional de Enfermedades Neoplásicas, Departamento de Cirugía en Abdomen, Lima, Peru
bAix Marseille Université, UMR912 SESSTIM INSERM-IRD-AMU, Centre d'Epidémiologie et de Santé Publique
des Armées, Marseille, France
c Instituto Nacional de Enfermedades Neoplásicas, Departamento de Patología, Lima, Peru
d Institut Pasteur, Unité Organisation Nucléaire et Oncogenèse, Paris, France
e Institut National de la Santé et de la Recherche Médicale, Paris U993, France
fUniversité de Toulouse, UPS, UMR152 PHARMADEV, Université Toulouse 3, Toulouse, France
g Institut de Recherche pour le Développement, UMR152 PHARMADEV, Vientiane, Laos
h Institut de Recherche pour le Développement, UMR152 PHARMADEV, Lima, Peru
*Corresponding author at: Representation IRD in Peru, Casilla 18-1209, Lima 18, Peru.
E-mail address: stephane.bertani@ird.fr (S. Bertani).
Abstract
In the developing world, most patients with hepatocellular carcinoma present
with advanced-stage disease, considered to be incurable based on current
therapeutic algorithms. Here, we demonstrate that curative liver resection is
achievable in a portion of Peruvian patients not addressed by these treatment
algorithms. We conducted a retrospective cohort study of 253 hepatocellular
carcinoma patients that underwent a curative hepatectomy between 1991 and
2011 at the National Cancer Institute of Peru. The median age of the cohort was
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36 years, and merely 15.4% of the patients displayed cirrhosis. The average
tumor size was over 14 cm in diameter, resulting in 76.3% of major
hepatectomies performed. The 5- and 10-year survival probability estimates
were 37.5% and 26.2%, respectively. Age (>44 vs. ≤44 years old; P = 0.005),
tumor size (>10 cm vs. ≤10 cm in diameter; P = 0.009), cirrhosis (P < 0.001),
satellite lesions (P < 0.001), macroscopic vascular invasion (P < 0.001),
allogeneic blood transfusion (P = 0.011), and spontaneous rupture of the tumor
(P = 0.006) were independent predictive factors for prognosis. Hepatocellular
carcinomas in Peru are characterized by a distinct clinical presentation with
notable features compared with those typically described throughout relevant
literature. Despite a large number of advanced-stage hepatocellular carcinomas,
the outcomes of liver resection observed in the present study were in good
standing with the results previously described in other series.It thus appears that
staging systems and associated therapeutic algorithms designed for use in the
developed world remain inadequate in certain populations, especially in the context
of Peruvian patients. Our findings suggest that clinicians in the developing world
should reconsider management guidelines pertaining to hepatocellular carcinoma.
Indeed, we hypothesize that, in developing countries, a strict adherence to these
therapeutic algorithms might create a selection bias resulting in the dismissal of
patients who could eventually be treated.
Keywords: Health sciences, Pathobiology of cancer, Cancer, Treatment of
cancer
1. Introduction
We have described the peculiar clinical presentation of hepatocellular carcinoma
(HCC) observed in the patients examined at the National Cancer Institute of
Peru [1]. Remarkably, half of these patients are under 40 years of age
presenting with massive primary tumors in the liver uniquely characterized by
extremely low rate of cirrhosis and a relatively low rate of tumor invasiveness.
This unique pathophysiological pattern of HCC coincides with a distinct
mutation spectrum featuring genetic insertions and deletions, in contrast with the
transitions and transversions paramount to the mutation spectra of HCCs from
North Africa, North America, East Asia, and Europe [2]. These findings suggest
that an uncommon and unique tumor process occurs in the Peruvian patient
population. Likewise, the distribution of the HCC-related risk factors in Peru is
rather unusual with low prevalence of alcohol abuse, non-alcoholic
steatohepatitis, and chronic hepatitis C. In addition, hepatitis B virus (HBV), the
major etiologic agent of primary liver cancer in the country, follows an
unconventional pattern: while primary liver cancer risk is correlated with
elevated HBV viral loads in Eastern Asia, almost half of HBV-associated HCCs
develop in a context of occult infection in Peru [1].
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The global incidence of HCC has doubled during the last two decades, with the
highest burden arising in the developing world [3,4]. To date, curative
treatment of HCC relies primarily on surgical intervention, and particular for
developing countries, on rarely performed liver resections. In this context, a vast
majority of patients visit physicians with advanced-stage cancer, drastically
limiting the use of liver transplantation and percutaneous ablation for treatment.
As a consequence, HCC is particularly lethal in the Global South. Worldwide,
82.8% of liver cancer cases occur in the developing world, which also accounts
for 83.6% of liver cancer-related deaths [4]. Thus, new affordable methods for
early detection and intervention are needed to improve patient outcomes.
In order to guide practitioners in clinical management strategies, various
therapeutic algorithms based on the stratification of the patients with HCC have
been elaborated by groups of experts from North America, East Asia, and
Europe. These staging systems have been compared to each other using cohort
studies, conducive to build international consensus [5, 6]. However, the at times
limited performance of the current therapeutic algorithms probably stems in part
from their lack of interoperability in different populations of patients. Based on
our long-term practice in primary liver cancer management in Peru, we suspect
that some of these algorithms do not account for patients' groups, notably those
from developing countries.
Here we present the data from 20 years of liver resection practice for HCC in
Peru, in which massive tumors on non-cirrhotic livers in juvenile patients were
prevailing. Specifically, this study was conducted retrospectively within a cohort
assembled by analyzing the medical records of patients with HCC who
underwent curative liver resection. Taking into consideration the peculiar
clinical presentation encountered in Peru (a country in a hitherto neglected
world region regarding studies of primary liver cancer), we think that our
experience in the management of HCC can provide valuable information for the
international community of health professionals on the development and usage
of such staging systems. We are also convinced that our experience can lead in
many instances to local reconsiderations of the strategy for the surgical
management of HCC. Finally, we emphasize the necessity of searching for a
truly multiregional consensus, taking into account local contexts.
2. Materials and methods
2.1. Ethics statement
Written consent was given by the patients for their information to be stored in
the Department of Cancer Statistics and Epidemiology of the National Cancer
Institute of Peru, and used for research. The study conforms to the ethical
principles contained in the Declaration of Helsinki, and was approved by the
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Human Subjects Committee of the National Cancer Institute of Peru (Protocol
Number #INEN10-05).
2.2. Patients' data collection
Between January 1991 and December 2011, a total of 339 patients with HCC
were operated on in the Department of Abdominal Surgery of the National
Cancer Institute of Peru. From this initial cohort, we selected a series of 253
patients with no extrahepatic metastases who underwent curative hepatectomy,
i.e. complete (R0) resection of the tumoral liver lesions, ensuring tumor-free
margins. The 86 patients excluded from this study were individuals who
underwent partial (R2) resection (n = 70) or orthotopic liver transplantation
(n = 2), with synchronous and secondary malignancies (n = 12), or for whom
the medical record was not exhaustive (n = 2). The dataset included the patients'
medical records, hepatitis B and C serology, preoperative liver function, alpha-
fetoprotein (AFP) serum level, perioperative morbidity and mortality, hospital
length of stay, as well as HCC recurrence and survival until August 2015.
2.3. Surgical procedure
Anatomical resection was the preferential treatment, but was not performed on
patients with cirrhosis. In cases of cirrhotic liver, only patients with Child-Pugh
class A were considered eligible for major hepatic resection, whereas patients with
Child-Pugh class B were offered minor hepatic resection. Interventions were
performed through midline, J-shaped, or bilateral subcostal abdominal incision,
according to the tumor location and the physical characteristics of the patient.
After incision, the abdominal cavity was extensively explored in order to discard
any suggestions of additional hepatic disease, and the status of the future remnant
liver was evaluated. This examination has been complemented by ultrasound
exploration since 2000. After detaching the hilar plate, we started the afferent
vascular control with the ligation and the division of the arterial and portal pedicles
at the hilum. Suprahepatic veins were controlled outside the liver. Pringle or
hemi-Pringle maneuvers were performed pro re nata. Total hepatic vascular
exclusion was performed for tumors involving inferior vena cava or hepatic veins.
Since 2001, we employed the anterior approach with or without a hanging
maneuver in order to prevent tumor embolism. Liver parenchymal transection was
performed by crush-clamping. Medium-sized blood vessels and bile ducts were
ligated, while the smallest ones were cauterized. After the removal of the surgical
piece, we achieved hemostasis by cauterizing liver bed bleeding by using an argon
plasma coagulator or a hemostatic dissection device. Finally, a closed drainage
system was installed. After surgical intervention, it was mandatory to admit
cirrhotic patients to the intensive care unit of the National Cancer Institute of Peru.
Patients without cirrhosis, however, were transferred to the intensive care unit at
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the discretion of the surgical team, based on the patient's post-operative health
status. Patients were monitored throughout their hospital stay, and the drain was
removed when the biliary fistula was discarded. Adjuvant chemotherapy was not
routinely administered.
2.4. Patients' follow-up
Patients had an extensive checkup twice during the first month after leaving
hospital, then every two months during the first year, and finally every four
months from the third year onward. [5_TD$DIFF]Liver regeneration and function were
respectively assessed by abdominal computed tomography scan and liver
function tests, including monitoring of the AFP serum level. While AFP
concentration was above 10 ng/mL, the eventuality of recurrent or metastatic
HCC was assessed by abdominal ultrasound and chest and bone radiographs. If
necessary, the exam was completed by computed and positron emission
tomographies. In cases of intrahepatic recurrence, the feasibility of surgical
intervention was promptly evaluated, and when possible, tumor re-resection was
performed quam primum. When recurrent HCC was unresectable, palliative
treatments, such as intra-arterial chemoembolization, percutaneous ethanol
injection, radiofrequency ablation, or tyrosine-kinase inhibitor chemotherapy,
were applied. Surgical pulmonary resection was carried out in cases of single
lung metastasis. Bone metastases were treated with radiation therapy. [6_TD$DIFF] In cases
without any follow-up, the National Registry of Identification and Civil Status
of Peru was solicited in order to determine the fate of the patient.[7_TD$DIFF]
2.5. Pathology report
Pathologists determined the macroscopic tumor size (i.e., longest chord measured),
the nodule number, the presence of vascular invasion, and the structure of the
non-tumoral liver parenchyma. HCC and non-tumoral liver diagnostic features
were confirmed on hematoxylin and eosin-stained liver sections. The tumor grade
was assessed according to the American Joint Committee on Cancer [7].
2.6. Statistical analysis
Survival probability estimates were calculated by the Kaplan–Meier method
from the date of surgery [8]. Log-rank test was used for survival distribution
comparison [9]. Postoperative deaths were included in the survival analysis, and
subsequent decease from any cause was considered an event. Potential
predictors of survival were evaluated using the Cox proportional-hazards
regression model [10]. Statistical analyses were performed with an alpha
significance level 0.05, using IBM SPSS Statistics software version 19.0.
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3. Results
3.1. Clinical presentation of hepatocellular carcinoma
Table 1 shows an overview of the clinical features of the 253 patients with
complete resection at the time of surgery operated in the Department of
Abdominal Surgery of the National Cancer Institute of Peru between January
1991 and December 2011. Over this 20-year period, an examination of the
patient population structure did not reveal a noticeable evolution in terms of
tumor presentation and clinical pathology and chemistry. The mean patient age
was low; half of the patients were less than 36 years old. The average tumor
size was over 14 cm in diameter, 73% of the patients presented with a tumor
larger than 10 cm. The predominant histopathological architecture of the tumors
was the trabecular pattern (70%), whereas fibrolamellar carcinomas represented
a small minority of the cases (1.6%) despite the overall young age of the cohort.
Major vascular invasion occurred only in 11% of the cases, all of them with a
tumor larger than 10 cm in diameter. Merely 15% of the resections were
performed on cirrhotic livers.
3.2. Hepatic resection category
Table 2 presents descriptive statistical results for the resection category. The
largest majority of the liver cancer resections, i.e. 76.3%, were major
hepatectomies, frequently extended to segment 1. Such a high ratio is rarely
found in relevant literature, in which major hepatectomy represents often a
minority of intervention [13].
3.3. Postoperative period, recurrence pattern, and cancer
survival
Table 3 details the postoperative morbidity (grades I to IV) and mortality (grade
V). Immediate postoperative bleeding and liver failure were the most frequent
and severe complications.The 30- and 90-day postoperative mortality rates were
of 5.1% and 7.1%, respectively. Table 4 summarizes the descriptive statistic results
for recurrence. In the follow-up period, 59% of the patients developed recurrence,
and 15.5% of them underwent re-resection. Fig. 1A shows the overall and
recurrence-free survival rates in the 20 years post-surgery [8_TD$DIFF](P = 0.0033). The
5- and 10-year survival probability estimates were 37.5% and 26.2%, respectively.[9_TD$DIFF]
The 5- and 10-year recurrence-free survival probability estimates were 22.9% and
16.2%, respectively. Fig. 1B displays the survival rates in the 20 years post-surgery
with patients stratified according to the Barcelona-Clinic Liver Cancer (BCLC)
stage disease; eight (3.2%) patients having BCLC A stage disease, 214 (84.6%)
having BCLC B, and 31 (12.3%) having BCLC C [15, 16]. The 5-year survival
probability estimates for patients with BCLC stages A and B were 50% and 36.8%,
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Table 1. Baseline demographic and clinical features of the patient population
investigated.
Feature Parameter Number Percentage
Cohort Headcount 253 100
Age Mean ± SD 41.9 ± 21.4 n/a
Median 36 n/a
Range [3–89] n/a
Interquartile range 39 n/a
Gender Female 103 40.7
Male 150 59.3
Cirrhosis Absent 214 84.6
Present 39 15.4
HBsAg Negative 141 55.7
Positive 112 44.3
Anti-HCV* Negative 194 96.5
Positive 7 3.5
Tumor size (cm) Mean ± SD 14.2 ± 5.9 n/a
Median 14.5 n/a
Range [2–33] n/a
Interquartile range 8.4 n/a
<5 15 5.9
[5–10] 53 20.9
>10 185 73.2
Multinodular tumors Present 78 30.8
Bilobar tumors Present 80 31.6
Child-Pugh class** A 30 76.9
B 9 23.1
Vascular invasion Macro 29 11.5
Micro 64 25.3
Negative 160 63.2
Histopathology Trabecular 177 70
Acinar 10 4
Compact 17 6.7
Mixed trabecular and acinar 36 14.2
Sarcomatoid 9 3.5
Fibrolamellar 4 1.6
AFP (ng/mL) Mean ± SD 93,026 ± 241,792 n/a
Median 2651 n/a
Interquartile range 56,826.8 n/a
(Continued)
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respectively; while the 10-year survival probability estimates were 25% and 22.1%,
respectively (P = 0.48). The 5-year survival probability estimate for patients with
Table 1. (Continued)
Feature Parameter Number Percentage
Albumin (g/L) Mean ± SD 38.7 ± 9.7 n/a
Median 39 n/a
Interquartile range 10 n/a
Alkaline phosphatase (U/L) Mean ± SD 187.3 ± 205.8 n/a
Median 129 n/a
Interquartile range 159 n/a
Alanine transaminase (U/L) Mean ± SD 63.2 ± 90.2 n/a
Median 40 n/a
Interquartile range 77 n/a
Aspartate transaminase (U/L) Mean ± SD 100.2 ± 115.6 n/a
Median 60 n/a
Interquartile range 40 n/a
Direct bilirubin (μmol/L) Mean±SD 7.3 ± 29.7 n/a
Median 2 n/a
Interquartile range 4.1 n/a
Indirect bilirubin (μmol/L) Mean±SD 10.2 ± 13.5 n/a
Median 8 n/a
Interquartile range 18.5 n/a
Total bilirubin (μmol/L) Mean ± SD 18.2 ± 41 n/a
Median 12 n/a
Interquartile range 14.2 n/a
Gamma-glutamyl transferase (U/L) Mean ± SD 288 ± 1,210 n/a
Median 124 n/a
Interquartile range 158 n/a
Prothrombin time (s) Mean ± SD 13.1 ± 1.7 n/a
Median 12.8 n/a
Interquartile range 2.1 n/a
International normalized ratio Mean ± SD 1.1 ± 0.2 n/a
Median 1.1 n/a
Interquartile range 0.2 n/a
Percentages are expressed as ratio of the 253 patients investigated for the considered parameter,
except for (*) hepatitis C infection (n = 201) and (**) Child-Pugh score in cirrhotic patients
(n = 39). Histopathological architecture was defined according to the classification of tumors of the
digestive system of the World Health Organization [11]. Mean values are presented with ± Standard
Deviation (SD). AFP = alpha-fetoprotein; HBsAg = HBV surface antigen; HCV = hepatitis C virus;
n/a = not applicable.
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Table 2. Hepatic resection categories.
Hepatic resection category Subcategory Number Extended to segment 1
Major hepatectomy (76.3%) Right trisectionectomy 37 7
Left trisectionectomy 16 12
Right hepatectomy 85 6
Left hepatectomy 55 36
Minor hepatectomy (23.7%) Right anterior and left medial sectionectomies 9
Right posterior sectionectomy 1
Left lateral sectionectomy 12
Left medial sectionectomy 5
Segmentectomy 1 2
Segmentectomy 3 1
Segmentectomy 5 1
Segmentectomy 6 2
Segmentectomy 8 2
Bisegmentectomy 4,5 4
Bisegmentectomy 5,6 14
Bisegmentectomy 7,8 1
Wedge 6
Total 253 61
Hepatic resection categories were defined according to the Brisbane 2000 Terminology of Liver Anatomy and Resections [12].
Table 3. Postoperative morbidity and mortality.
Complication Grade I Grade II Grade IIIa Grade IIIb Grade IV Grade V Total
Bile leakage 2 2 2 1 7
Cerebrovascular accident 1 1
Evisceration 2 2
Hemorrhaging 1 2 5 3 11
Intestinal obstruction 1 1
Intra-abdominal abscess 4 4
Liver failure 1 8 6 15
Pleural effusion 1 1
Pneumonia 1 2 3
Pulmonary embolism 8 1 9
Total 8 24 2 7 13 54
Postoperative morbidity and mortality were categorized according to the Dindo–Clavien
classification [14].
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BCLC stage C was only 3.2% and differed significantly from the one of both
BCLC stages A and B (P = 0.0026 and <0.0001, respectively). Fig. 1C shows the
survival rates of patients with or without cirrhosis in the 20 years post-surgery
(P < 0.0001). The 5-year survival probability estimate among cirrhotic patients
was 11.4%; whereas the 5- and 10-year survival probability estimates among
non-cirrhotic patients were 40.1% and 27.9%, respectively.
3.4. Potential predictors of survival
Table 5 presents the results of the multivariate analysis for factors related to
survival. Among all the parameters tested, the age, the size of the tumor, the
presence of cirrhosis, satellite lesions, or macroscopic vascular invasion, as well
Table 4. Pattern of recurrence after hepatic resection.
Recurrence pattern Status Number Percentage
Recurrence* Yes 142 59.2
No 98 40.8
Recurrence presentation** Intrahepatic 72 50.7
Extrahepatic 47 33.1
Intra- and extra-hepatic 23 16.2
Re-resection*** Intrahepatic 14 19.4
Extrahepatic 7 14.9
Intra- and extra-hepatic 1 4.3
Any reappearance of HCC was considered as a recurrence regardless the time period after the initial
intervention. Percentages were calculated with (*) 240 patients, excluding the 13 patients who died
during the postoperative period (Table 3); (**) 142 patients with recurrent HCC; (***) the number
of patients in relation to the site of recurrence, i.e. 72 for intrahepatic recurrence, 47 for extrahepatic
recurrence, and 23 for intra- and extra-hepatic recurrence.
[(Fig._1)TD$FIG]
Fig. 1. Kaplan–Meier cumulative survival curves. (A) Overall and recurrence-free survivals are
represented by blue and green curves, respectively. (B) Survivals for patients with BCBL A (n = 8),
B (n = 214), and C (n = 31) stages disease are represented in green, blue, and yellow curves,
respectively. (C) Survivals for patients with (n = 39) and without (n = 214) cirrhosis are represented
in blue and green curves, respectively.
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as allogeneic blood transfusion and spontaneous rupture of the liver tumor
before surgery, were independent predictive factors for prognosis (P < 0.05).
4. Discussion
The aims of cancer staging systems and associated therapeutic algorithms are to
rationally predict patient prognosis and to guide practitioners in deciding
treatment allocation. Multiple staging systems have been developed and
compared for HCC cases in order to determine which ones best predict
prognosis. Indeed, the intended purpose of international collaboration between
experts is to move towards an international consensus on the management of
HCC [5, 6]. As a consequence of the neoplastic heterogeneity of HCC, this
objective has not yet been achieved.
Since the first classification by Okuda and colleagues [17], various staging systems
have been developed and notably include those of the American Joint Committee
on Cancer [7], the Cancer of the Liver Italian Program [18], the French Group for
the Study and the Treatment of HCC [19], the Chinese University of Hong Kong
[20], the Japan Society of Hepatology [21], and the Liver Cancer Study Group of
Japan [22]. The BCLC staging system is currently the most widely accepted
therapeutic flow-chart across the world [15, 16], adopted by the European
Association for the Study of the Liver and the American Association for the Study
of Liver Disease [23, 24]. In these therapeutic algorithms, several clinico-
biological parameters, such as AFP and bilirubin serum levels and presence of
vascular invasion and metastases are taken into account to stratify patients and
decide treatment allocation. Among those parameters, tumor features, and notably
tumor size, are certainly the most critical in choosing between curative treatment
and palliative care. Commonly, only early stage HCCs, up to 2 or 3 cm in diameter
Table 5. Multivariate analysis for factors related to survival.
Variable Odds ratio 95% confidence interval
(lower – upper)
P value
Age (>44 vs. ≤44 years old) 1.54 1.140 – 2.103 0.005
Tumor size (>10 cm vs. ≤10 cm in diameter) 1.74 1.152 – 2.638 0.009
Cirrhosis (presence vs. absence) 2.92 1.927 – 4.447 0.000
Macroscopic portal vein tumor thrombosis (presence vs. absence) 2.73 1.767 – 4.220 0.000
Allogeneic blood transfusion (yes vs. no) 1.48 1.094 – 2.017 0.011
Satellite lesions (presence vs. absence) 2.25 1.634 – 3.120 0.000
Spontaneous rupture of the liver tumor before surgery (yes vs. no) 2.14 1.244 – 3.689 0.006
The age cutoff was chosen according to the in-between age calculated previously [1]. The odds ratio represents the exponentiation
of the intercept in the null model.
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(depending on which flow-chart is used), are considered to be candidates for
resection [25, 26].
In the last couple of years, a debate has taken place about the necessity of
adherence to such staging systems [27, 28, 29, 30, 31]. In fact, most of these
systems have been conceived by experts attending patients affected with HCC in
a clinical context where cirrhotic liver represents the very large majority of the
cases. However, HCC is among the most diversified types of cancer in terms of
clinical presentation and molecular signature [32, 33], due in part to the variety
of associated risk factors.
The team of the Department of Abdominal Surgery at the National Cancer
Institute of Peru attends more than 120 patients a year diagnosed with primary
liver cancer, and performs about 20 liver resections annually for HCC. These
numbers have been steadily increasing during the last decades, due in part to the
improvements to the national healthcare system in Peru that allow earlier patient
detection, but also to the increasing trend in incidence of primary liver cancer in
Latin America [4]. We recently described Peruvian patients developing HCC at
a young age, and then correlated this clinical presentation to a peculiar mutation
spectrum [1, 2]. In comparison with literature stating that fibrolamellar
carcinoma occurs commonly in children and young adults [34], the very large
majority of our patients developed HCC with a trabecular pattern (Table 1). To
the best of our knowledge, Peruvian patients are remarkable for the consistent
presentation of massive HCC, exceeding AFP serum level, and very low rate of
cirrhosis, in distinct contrast with most observational studies described in cancer
literature [1]. According to the staging systems currently available, the large
majority of our patients would be scored at an advanced stage of disease with a
poor prognosis (Table 1) [15, 16]. As a consequence, these patients would be
mostly considered ineligible for curative liver resection.
Indeed, the Latin American Association for the Study of the Liver has recently
published clinical practice guidelines for the management of HCC in the region
[35]. According to the authors, these guidelines are based on an international
consensus, outlining the BCLC staging system. In our case, the application of
these guidelines would result in the dismissal of those patients who received
surgery. For instance, if we had applied the criteria of the BCLC staging
system, only eight patients from our initial cohort would have been considered
as candidate for liver resection, whereas our surgical strategy allowed us to treat
214 additional patients leading to a 5-year survival ratio of 36.8% (Fig. 1B).
This result has to be offset with the fact that we performed intervention only on
15% of the overall HCC patients visiting the National Cancer Institute of Peru
during this period. This is why we are convinced that the authority of such
prescribed guidelines should be discussed and their contextual applications
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should be explicitly addressed. In fact, the adherence to international guidelines
has been already questioned in real-life practice by some physicians [29, 30,
31], while a more contextualist approach has been suggested by others [36, 37].
From our perspective, only the recommendations of the Asian Pacific Association
for the Study of the Liver would reflect our patient population [38]. This treatment
algorithm developed in 2010 is distensible and eventually considers liver resection
for a patient with HCC that is confined to the liver and technically, surgically
resectable with sufficient remnant healthy liver to insure the vital hepatic
functions. Through the evolution of our treatment, no suitable therapeutic flow-
charts were identified; therefore, we have developed our own specific approach in
the management of HCC based on our long-term experience in clinical practice in
Peru. Our decision tree for curative liver resection was relatively concise, with few
nodes. In using this approach, we first determined the tumor location site, i.e.
whether the liver tumor is extra- or intra-hepatic. In cases with an intrahepatic
tumor, we assessed the size of the remnant liver and its function by a blood test,
which included measurement of the serum levels of albumin, alanine and aspartate
aminotransferases, total and direct bilirubin, alkaline phosphatase, and gamma-
glutamyl transpeptidase serum levels (Table 1). In addition, we calculated the
prothrombin time and the international normalized ratio (Table 1). When this was
conclusive, the patient was considered as a candidate for curative liver resection,
regardless of the size of the tumor. In our hands, this approach, based on the
absence of cirrhosis and the lack of evidence of extrahepatic tumor lesions, made
liver resection the most effective treatment for nearly 15% of our patients. Unlike
other cohort studies found in the literature, most resections performed in our study
were major hepatectomies due to the size and the location of the tumors exsected
(Table 2). The surgical outcomes observed in our resected patient cohort, as well
as survival rates, were in good standing compared with other cohort studies found
in relevant literature (Fig. 1, Table 3 and Table 4) [13]. Furthermore, this result
was attained with a cohort of patients who were mostly less than 37 years old, in
spite of the tumor size and the fact that carcinomas had virtually no fibrolamellar
variants [12_TD$DIFF](Table 1), a histotype reputed to be less disseminative [13_TD$DIFF] 39].
Several regions of the world, encompassing most of the so-called Global South,
i.e. Africa, Latin America and Caribbean, Central, West, and Southeast Asia,
Melanesia, and Polynesia (as defined by the International Agency for Research
on Cancer [4]), have not been closely examined regarding the natural history
and the most common clinical presentation of HCC. Most of these countries do
not have the benefit of population-based cancer registries, and the coverage of
cancer information is obtained sparsely by extracting data from patients' medical
records. Yet, in developing countries, patients with liver cancer which would be
considered advanced are rapidly dismissed from the chain of care [40]. This
situation is partly due to the lack of alternative therapeutic support after a basic
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doctor's visit, during which a poor prognosis may be given according to the
current staging systems. These poorly documented patients are often among the
most deprived people, frequently living in remote areas [4, 40]. It is thus
difficult to determine their fate once dismissed from the chain of care. As a
consequence, a frequently unusual clinical presentation of HCC, as reported in
Peru [1, 2], that contradicts the situation commonly described in available
staging systems, could easily go unnoticed, despite the fact that some of these
tumors would eventually be treatable. A rigid adherence to the current
therapeutic algorithms in developing countries, without taking into account both
local epidemiology and clinical presentation [3], might thus lead to a selection
bias culminating in damaging adverse effect on a fraction of the local patients,
and then, self-perpetuating the local application of these algorithms. Brought
back to the Peruvian context, predictive factors such as those listed in Table 5
could be of special interest to build the foundations of a context-related
interventional flow-chart.
Current data reports discrepancies in the performance of therapeutic algorithms
typically used for patient populations originating in North America, East Asia,
or Europe. Thus, it is highly plausible that these differences exist when these
therapeutic algorithms are applied to regions which are underserviced with poor
documentation of liver cancer outcomes. Therefore, there must be an in-depth
discussion for a contextualist approach to HCC surgery in those regions. In this
regard, new considerations for tumor size and morphology reflected in recent,
7th edition update of the tumor-node-metastasis classification [41, 42], as well
as the recommendations of the Asian Pacific Association for the Study of the
Liver [38], represent interesting advances, as they open up new intervention
possibilities.
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